Aporphine and oxoaporphine compounds and pharmaceutical use...

Details Aporphine and oxoaporphine compounds and pharmaceutical use... Aporphine and oxoaporphine compounds and pharmaceutical use...

2007-11-13

2007-11-13

Seaman, Margaret D (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

11439076

ABSTRACT:
The invention provides aporphine and oxoaporphine compounds that may be used to manufacture a medicaments for preventing or treating vascular dysfunctions that may result in ischemic and metabolic diseases or preventing complications associated with these diseases in human and mammal. The ischemic diseases may include ischemic cerebral apoplexy, ischemic cerebral thrombosis, ischemic cerebral embolism, hypoxic ischemic encephlopathy, ischemic cardiac disease or ischemic enteropathy etc. The metabolic disease may include diabetes-induced vascular diseases, such as hypertension, atherosclerosis, peripheral artery or venous thrombosis, retinopathy and nephropathy. Methods for treating ischemic and metabolic diseases or preventing complications are also disclosed.

REFERENCES:
patent: 6313134 (2001-11-01), Su et al.
Lan et al.,J.Nat.Prod.,“Cytotoxic styrylpyrones form Goniothalamus amuyon”,2003, vol. 66, pp. 487-490.
Zhang et al., Chem.Pharm.Bull.,“Sesquiterpenes and alkoloids fromLindera chuniiand their inhibitory activities against HIV-1 integrase”, 2002, vol. 50,pp. 1195-1200.
Khroyan et al., J. of Pharmacology and Experimental Therapeutics, “Dopamine D1-and D2Like receptor mechanisms in relapse to cocaineseeking behaviour: effects of selective antagonists and agonists”, 2003, vol. 66,pp. 680-687.
Chiou et al., J.Nat.Prod., “Litebamine N-homologues: preparation and anti-acetylcholinesterase activity”, 1998,vol. 61,pp. 46-50.
Lee et al., Tetrahedron Letters, “preparation of phenanthrene alkaloids via solvolysis of 2-hydroxyaporphines”1995,vol. 36,pp. 1531-1532.
Hsieh et al., J.Nat.Prod., “The alkaloids ofArtabotrys uncinatus”,2001,vol. 64, pp. 1157-1161.
Matteo et al., J.Am.Chem.Soc.,“Correlation between molecular structure and helicity of induced chiral nematics in terms of short-range and electrostatic-induction interactions. The case of chiral biphenyls”,2001,vol. 123,pp. 7842-7851.
Ribeiro et al., Phtomedicine,“In vitro dose dependent inverse effect of nantenine on synaptosomal membrane K-p-NPPase activity”,2001, vol. 8,pp. 107-111.
Sun et al., Journla of pharmaceutical and Biomedical analysis, “Determination ofLauraceous aporphinealkaloids by high-performane liquid chromatography”,1996,vol. 14,pp. 1383-1387.
Chen et al., Planta Medica, “Cytotoxic constituents fromAquilegia ecalcarata”,2002,vol. 68, pp. 554-556.
Jantan et al., Planta Medica, “Inhibition of plantelet-activating factor receptor binfing by aporphine and phenanthrenoid alkaloids from aromadendron elegans”,2001,vol. 7, pp. 466-467.
Nissanka et al., Phytochemistry, “Antimicrobial alkaloids fromZanthoxylum tetraspermumandcaudatum”, 2001,vol. 56,pp. 857-861.

Affiliated with

Also associated with

Rating

Aporphine and oxoaporphine compounds and pharmaceutical use... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aporphine and oxoaporphine compounds and pharmaceutical use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aporphine and oxoaporphine compounds and pharmaceutical use... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3869821